Dianthus Therapeutics, Inc. $DNTH Shares Bought by Vestal Point Capital LP

Key Points

• Vestal Point Capital LP increased its stake in Dianthus Therapeutics by 58.1% in Q1, owning 1,700,069 shares worth approximately $30.84 million.
• Several analysts have given Dianthus Therapeutics a consensus rating of "Buy", with Target prices ranging from $34.00 to $54.00.
• Dianthus Therapeutics reported a Q2 EPS of ($0.88), missing expectations, and predicted a net loss with a negative return on equity of 34.72%.

Vestal Point Capital LP lifted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 58.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,700,069 shares of the company's stock after purchasing an additional 625,069 shares during the quarter. Dianthus Therapeutics comprises about 2.2% of Vestal Point Capital LP's portfolio, making the stock its 16th biggest position. Vestal Point Capital LP owned approximately 5.29% of Dianthus Therapeutics worth $30,839,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in DNTH. RA Capital Management L.P. boosted its position in shares of Dianthus Therapeutics by 53.6% in the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock worth $52,003,000 after purchasing an additional 1,000,333 shares in the last quarter. Braidwell LP grew its stake in Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock valued at $26,304,000 after purchasing an additional 712,902 shares during the last quarter. Octagon Capital Advisors LP grew its stake in Dianthus Therapeutics by 20.8% during the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after purchasing an additional 363,500 shares during the last quarter. Candriam S.C.A. purchased a new stake in Dianthus Therapeutics during the 1st quarter valued at about $4,510,000. Finally, Janus Henderson Group PLC grew its stake in Dianthus Therapeutics by 14.4% during the 4th quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company's stock valued at $23,607,000 after purchasing an additional 136,314 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on DNTH shares. Robert W. Baird dropped their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. William Blair started coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an "outperform" rating on the stock. Finally, Wedbush boosted their price target on Dianthus Therapeutics from $34.00 to $42.00 and gave the company an "outperform" rating in a research note on Thursday, August 21st. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $54.00.

Dianthus Therapeutics Stock Up 7.5%

Shares of DNTH stock traded up $1.84 on Friday, hitting $26.50. The company had a trading volume of 679,673 shares, compared to its average volume of 359,164. The firm has a market cap of $853.04 million, a P/E ratio of -8.15 and a beta of 1.46. The company has a 50-day moving average price of $21.27 and a 200-day moving average price of $20.03. Dianthus Therapeutics, Inc. has a twelve month low of $13.36 and a twelve month high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.